Atrial fibrillation

Mount Sinai Journal of Medicine

Volumn 73, Issue 1, 2006, Pages 482-492

  Andrews, Marc ^a   Nelson, Bret P ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

Arrhythmia; Atrial; Fibrillation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHLORIDE; DIGOXIN; DILTIAZEM; DOFETILIDE; ESMOLOL; FLECAINIDE; GLUCONATE CALCIUM; IBUTILIDE; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM; METOPROLOL; PROPAFENONE; PROPRANOLOL; SEDATIVE AGENT; VERAPAMIL; WARFARIN; XIMELAGATRAN;

ANALGESIA; ANTICOAGULANT THERAPY; ATRIOVENTRICULAR BLOCK; BOLUS INJECTION; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DISEASE CONTROL; DISEASE MARKER; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART BLOCK; HEART CATHETERIZATION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART RATE AND RHYTHM; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPOTENSION; HYPOVOLEMIA; INFECTION; INOTROPISM; MEDICAL DECISION MAKING; META ANALYSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; QT PROLONGATION; RECEPTOR BLOCKING; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SAFETY; SINUS RHYTHM; THROMBOSIS; TORSADE DES POINTES; TREATMENT PLANNING;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; HEART RATE; HUMANS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS;

EID: 32144459950     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart study. Circulation 2004; 110:1042-1046.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation study. JAMA 2001; 285:2370-2375.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart study. Circulation 1998; 98:946-952.
4. Dorian P, Paquette M, Newman D, et al. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 2002; 143:984-990.
5. Luderitz B, Jung W. Quality of life in patients with atrial fibrillation. Arch Intern Med 2000; 10:1612-1617.
6. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339:659-666.
7. Oral H, Knight BP, Tada H, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation 2002; 105:1077-1081.
8. Skanes AC, Mandapati R, Berenfeld O, et al. Spatiotemporal periodicity during atrial fibrillation in the isolate sheep heart. Circulation 1998; 98:1236-1248.
9. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustained arrhythmia independent of focal discharge. Am Heart J 1959; 58:59-70.
10. Allessie MA, Lammers WJ, Bonke IM, Hollen J. Intra-atrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in the dog. Circulation 1984; 70:123-135.
11. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population based cohort: the Framingham Heart Study. JAMA 1994; 271:840-844.
12. Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164:1675-1678.
13. Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 2004; 164:1993-1008.
14. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96(7):2455-2461.
15. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation: the Framingham Heart study. Circulation 1994; 89:724-730.
16. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96:2455-2461.
17. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991; 22:983-988.
18. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke 1996: 27:1760-1764.
19. Upshaw CB. Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med 1997; 157:1070-1076.
20. Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000; 75:790-795.
21. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32(3):695-703.
22. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285(22):2864-2870.
23. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154:1449-1157.
24. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110:2287-2292.
25. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart study. JAMA 2003; 290:1049-1056.
26. Van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163(8):936-943.
27. Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials: the Stroke Prevention in Atrial Fibrillation investigators. Stroke 1999; 30:1223-1229.
28. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32(11):2575-2579.
29. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997; 336:1429-1434.
30. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 96(10):3542-3548.
31. Thambidorai SK, Parakh K, Martin DO, et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004; 94:805-807.
32. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Circulation 2001; 104:2118-2150.
33. Accardi AJ, Miller R, Holmes JF. Enhanced diagnosis of narrow complex tachycardias with increased electrocardiograph speed. J Emerg Med 2002; 22:123-126.
34. Herbert ME, Votey SR. Adenosine in wide-complex tachycardia. Ann Emerg Med 1997; 291:172-174.
35. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7(10):999-1007.
36. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of atrial fibrillation: the Framingham study. N Engl J Med 1982; 306:1018-1022.
37. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: advanced cardiovascular life support: 7D: the tachycardia algorithms. Circulation 2000;102 (8 Suppl):I158-II65.
38. Joglar JA, Hamdan MH, Ramaswamy K, et al. Initial energy for elective external cardioversion of persistent atrial fibrillation. Am J Cardiol 2000; 86:348-350.
39. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment and survival in the AFFIRM study. Circulation 2004; 109:1509-1513.
40. Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a TEE study. J Am Coll Cardiol 1995; 25:452-459.
41. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-1833.
42. Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial. Circulation 2004; 109:1973-1980.
43. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834-1840.
44. Al-Khatib SM, Shaw LK, Lee KL, et al. Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? Am J Cardiol 2004; 94:797-800.
45. Marshall DA, Levy AR, Vidaillet H, et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004; 141:653-661.
46. Hagens VE, Vermeulen KM, TenVergert EM, et al. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation - results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J 2004; 25:1542-1549.
47. Israel CW, Gronefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. J Am Coll Cardiol 2004; 43:47-52.
48. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344:1411-1420.
49. Burton J, Vinson DR, Drummond K, et al. Electrical cardioversion of emergency department patients with atrial fibrillation. Ann Emerg Med 2004; 44:20-30.
50. Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009-1017.
51. Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68:41-46.
52. Sodermark T, Jonsson B, Olsson A, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: a multicenter study from Stockholm. Br Heart J 1975; 37:486-492.
53. Lundstrom T, Ryden L. Chronic atrial fibrillation: long-term results of direct current conversion. Acta Med Scand 1988; 223:53-59.
54. Falcone RA, Morady F, Armstrong WF. Transesophageal echocardiographic evaluation of left atrial appendage function and spontaneous contrast formation after chemical or electrical cardioversion of atrial fibrillation. Am J Cardiol 1996; 78:435-439.
55. Goldenberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol 1994; 74(9):884-889.
56. Heywood JT, Graham B, Marais GE, Jutzy KR. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol 1991; 67:1150-1152.
57. Materne P, Legrand V, Vandormael M, et al. Hemodynamic effects of intravenous diltiazem with impaired left ventricular function. Am J Cardiol 1984; 54:733-737.
58. Phillips BG, Gandhi AJ, Sanoski CA, et al. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy 1997; 17(6):1238-1245.
59. Haft JI, Habbab MA. Treatment of atrial arrhythmias. Effectiveness of verapamil when preceded by calcium infusion. Arch Intern Med 1986; 146(6):1085-1089.
60. Dolan DL. Intravenous calcium before verapamil to prevent hypotension. Ann Emerg Med 1991; 20:588-589.
61. Kuhn M, Schriger DL. Low-dose calcium pretreatment to prevent verapamil-induced hypotension. Am Heart J 1992; 124:231-232.
62. Kolkebeck T, Abbrescia K, Pfaff J, et al. Calcium chloride before IV diltiazem in the management of atrial fibrillation. J Emerg Med 2004; 26:395-400.
63. Edoute Y, Nagachandran P, Svirski B, Ben-Ami H. Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents. J Cardiovasc Pharmacol 2000; 35:556-559.
64. Sagie A, Strasberg B, Kusnieck J, Sclarovsky S. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol 1991; 14(4):314-316.
65. Tateishi T, Nakashima H, Shitou T, et al. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol, and atenolol. Eur J Clin Pharmacol 1989; 36:67-70.
66. Hunt BA, Bottorff MB, Herring VL, et al. Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers. Clin Pharmacol Ther 1990; 47:584-591.
67. Murgatroyd FD, Gibson SM, Baiyan X, et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation 1999; 99:2765-2770.
68. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med 1991; 114:573-575.
69. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study. Eur Heart J 1995; 16:521-528.
70. American Heart Association. Advanced Cardiovascular Life Support guidelines. Circulation 2000; 102(Suppl I):I-86-I89.
71. Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001; 29(6):1149-1153.
72. Vardas PE, Kochiadakis GE, Igoumenidis NE, et al. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled trial. Chest 2000; 117:1538-1545.
73. Moran JL, Gallagher J, Peake SL, et al. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med 1995; 23(11):1816-1824.
74. Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol 2001; 79:287-291.
75. Yapa RS, Green GJ. Embolic stroke following cardioversion of atrial fibrillation to sinus rhythm with oral amiodarone therapy. Postgrad Med J 1999; 6:410-411.
76. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29:469-436.
77. Morris JJ. Electrical cardioversion of atrial fibrillation: immediate and long-term results and selection of patients. Ann Int Med 1966; 65:216-231.
78. Selzer A. Immediate and long term results of electrical cardioversion of arrhythmias. Prog Cardiovas Dis 1966; 9:90-104.
79. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23:208-216.
80. Resnekov L, McDonald L. Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electrocardioversion. Eur Heart J 1967; 29:926-936.
81. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-457.
82. Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004; 44:1557-1566.
83. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35:2362-2367.
84. Sam C, Massaro JM, D'Agostino RB Sr, et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart study). Am J Cardiol 2004; 94:947-951.
85. Harenberg J, Weuster B, Pfitzer M, et al. Prophylaxis of embolic events in patient with atrial fibrillation using low-molecular weight heparin. Semin Throb Hemost 1993; 19(Suppl):116-121.
86. Harenberg J, Huhle G, Piazolo L, et al. Long term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin Thromb Hemost 1997; 23(2):167-172.
87. Kim MH, Morady F, Conlon B, et al. A prospective, randomized, controlled trial of an emergency department-based atrial fibrillation treatment strategy with low-molecular-weight heparin. Ann Emerg Med 2002; 40:187-192.
88. Zeuthen EL, Lassen JF, Husted SE. Haemostatic activity in patients with atrial fibrillation treated with low-molecular-weight heparin before and after electrical cardioversion. J Thromb Thrombolysis 2004; 17:185-189.
89. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: randomized controlled trial. Lancet 2003; 362:1691-1698.